Respiratory failure & ventilation

A prospective clinical evaluation of new ECCO2R technology in mild to moderate acute respiratory distress syndrome (ARDS) patients: assessing ultra-lung-protective ventilation with PRISMALUNG+

Crit CarePublished Prospective multicentre single-group study

Authors' conclusion

This study demonstrates that hypercapnic acidosis occurring during ultra-low VT ventilation (ULPV) can be safely mitigated with ECCO₂R in mechanically ventilated patients with mild to moderate ARDS.

Study context

Population
Mechanically ventilated patients with mild to moderate ARDS, France16 with CRRT
Participants
58 participants
Exposure
Before vs after 24 h of ECCO2R with ultra-lung-protective ventilation (ULPV)
  • ECCO2Rn = 58
Outcome
Ventilation parameters, baseline vs 24 h
Follow-up
24 h
Methodological detailsstandardised ULPV protocol, April 2021 to December 2023
  • Standardised ULPV protocol
  • April 2021 to December 2023

Main finding

As reported in the abstract

  • VT decreased from 6.0 [6.0-6.1] to 4.0 [4.0-4.30] (p < 0.0001)
  • ∆P decreased from 12.0 [10.0-16.0] cmH2O to 10.0 [8.0-13.0] cmH2O (p < 0.0001)
  • Ventilatory ratio (VR) decreased from 1.7 [1.5-2.1] to 1.3 [1.0-1.6] (p < 0.0001)
  • Mechanical power decreased from 18.8 [15.0-22.0] J/min to 11.8 [8.8-15.5] J/min (p < 0.0001)
  • PaO2/FiO2 did not significantly change over time
  • Respiratory acidosis resolved: normalisation of pH and reduction in PaCO2

Observational data: associations, not effects.

Further findings

Peak hypercapnia and respiratory acidosis during VT reduction, before ECCO2R initiation

PaCO2 53.0 [50.0-55.0] mmHg
pH 7.30 [7.24-7.36]

Safety

Major bleeding events, intracranial hemorrhages, hemolysis · until discharge or day 28

No major bleeding events, intracranial hemorrhages, or hemolysis reported

Original publication

A prospective clinical evaluation of new ECCO2R technology in mild to moderate ARDS patients: assessing ultra-lung-protective ventilation with PRISMALUNG+. Crit Care. Published 6 January 2026. doi:10.1186/s13054-025-05827-4

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.